Reuters Health Information (2003-07-18): EU approves label change for Pegasys/Copegus used to treat hepatitis C
EU approves label change for Pegasys/Copegus used to treat hepatitis C
Last Updated: 2003-07-18 12:07:16 -0400 (Reuters Health)
ZURICH (Reuters) - The European Commission has approved a new approach to administering Roche's treatment for hepatitis C, the Swiss healthcare group said on Friday.
The change means physicians can vary the dosages of ribavirin given in combination with Pegasys (pegylated interferon alfa-2a), depending on the kind of the virus that patients have, Roche said.
Patients with the hard-to-treat type 1 virus would get 12 months of therapy with standard doses of Copegus--Roche's brand of ribavirin--while those with types 2 and 3 would get six months of treatment at lower levels of Copegus.
Roche said the change would allow patients to stop treatment as soon as warranted.